Compare BELFB & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | QURE |
|---|---|---|
| Founded | 1949 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2007 |
| Metric | BELFB | QURE |
|---|---|---|
| Price | $153.36 | $27.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $153.75 | $62.33 |
| AVG Volume (30 Days) | 186.0K | ★ 4.7M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $649,376,000.00 | $15,751,000.00 |
| Revenue This Year | $26.78 | N/A |
| Revenue Next Year | $6.19 | $229.18 |
| P/E Ratio | $29.84 | ★ N/A |
| Revenue Growth | ★ 23.70 | N/A |
| 52 Week Low | $58.00 | $5.89 |
| 52 Week High | $167.04 | $71.50 |
| Indicator | BELFB | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 33.83 |
| Support Level | $133.71 | $26.76 |
| Resistance Level | $152.26 | $28.50 |
| Average True Range (ATR) | 8.42 | 2.55 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 56.56 | 35.70 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.